FAILSAFE Fungal Antimicrobial Resistance Innovations for Low & Middle Income Countries: Solutions & Access For Everyone


FAILSAFE – Fungal AMR Innovations for LMICS: Solutions and Access For Everyone

The MRC Centre for Medical Mycology (MRC CMM) aims to deliver world-leading research that will substantially advance our understanding of fungal pathogenesis, host immunity and disease phenotypes, thereby enabling the generation and utilisation of skills and knowledge that will improve the prevention, diagnosis and treatment of fungal diseases in the future. Amongst the CMM activities that are actively working to increase capacity in medical mycology, the FAILSAFE project aims to provide combined global research and development (R&D), One Health and educational activities that will reduce the fungal disease burden in low and middle income countries (LMICs).

The FAILSAFE project will support innovative R&D mitigating the consequences of AFR (antifungal resistance), focusing on the themes of microbial pathogenesis, biomarkers and diagnostics, and the use of innovative platforms.

Solutions for antifungal drug resistance are urgently needed, and the new FAILSAFE project is funded by the UK Department of Health and Social Care’s Global AMR Innovation Fund (GAMRIF). This is a One Health UK aid fund that supports research and development around the world to reduce the threat of antimicrobial resistance (AMR) in humans, animals and the environment for the benefit of people in low- and middle-income countries.

Utilising £3.4 million across a 3-year period (2024 – 2027), the FAILSAFE project will support the delivery of multiple projects led by Network members worldwide, with a focus on developing tangible AFR products and solutions.

The FAILSAFE project is jointly led by Professor Gordon Brown and Professor Elaine Bignell from the University of Exeter, both of whom are Directors of the MRC CMM.